Use of a long acting somatostatin analogue in controlling life threatening ileostomy diarrhoea
- PMID: 6148992
- PMCID: PMC1443040
- DOI: 10.1136/bmj.289.6451.1027
Use of a long acting somatostatin analogue in controlling life threatening ileostomy diarrhoea
Abstract
A woman presented with persistent ileostomy diarrhoea unresponsive to conventional drug treatment and necessitating parenteral nutrition. Output was four to six litres of watery fluid per 24 hours while she was receiving oral nutrition and two to three litres when she was starved. Treatment with a long acting analogue of somatostatin (50 micrograms subcutaneously every 12 hours) reduced the ileostomy output to 2.0-2.5 litres/24 hours with an oral diet and the effluent became semiformed. Parenteral fluids could be stopped. Somatostatin may have a role in the treatment of secretory diarrhoea, but prospective controlled trials are necessary.
Similar articles
-
Effects of a long-acting somatostatin analogue in patients with severe ileostomy diarrhoea.Br J Surg. 1986 Feb;73(2):128-31. doi: 10.1002/bjs.1800730219. Br J Surg. 1986. PMID: 2868771 Clinical Trial.
-
[Treatment of chronic non-secretory diarrhea in ileostomy with the long-acting somatostatin analog SMS 201-995].Z Gastroenterol. 1988 Mar;26(3):166-8. Z Gastroenterol. 1988. PMID: 2900585 German.
-
Use of a long-acting somatostatin analogue (SMS 201-995) in controlling a significant ileal output in a 5-year-old child.J Pediatr Gastroenterol Nutr. 1987 May-Jun;6(3):466-70. doi: 10.1097/00005176-198705000-00026. J Pediatr Gastroenterol Nutr. 1987. PMID: 2892904
-
The role of somatostatin analogues in the treatment of refractory diarrhoea.Digestion. 1996;57 Suppl 1:107-13. doi: 10.1159/000201412. Digestion. 1996. PMID: 8813486 Review.
-
Treatment of endocrine and nonendocrine secretory diarrheal states with Sandostatin.Metabolism. 1990 Sep;39(9 Suppl 2):172-5. doi: 10.1016/0026-0495(90)90239-9. Metabolism. 1990. PMID: 2205786 Review.
Cited by
-
Remission of symptoms during long term treatment of metastatic pancreatic endocrine tumours with long acting somatostatin analogue.Br Med J (Clin Res Ed). 1986 Apr 12;292(6526):981-2. doi: 10.1136/bmj.292.6526.981. Br Med J (Clin Res Ed). 1986. PMID: 2870758 Free PMC article.
-
Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.Drugs. 1989 Nov;38(5):658-702. doi: 10.2165/00003495-198938050-00002. Drugs. 1989. PMID: 2689136 Review.
-
Clinical response to the long acting somatostatin analogue SMS 201-995 in a child with congenital microvillus atrophy.Gut. 1989 Jul;30(7):1020-4. doi: 10.1136/gut.30.7.1020. Gut. 1989. PMID: 2759484 Free PMC article.
-
Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal response to a mixed meal in acromegalic patients.J Endocrinol Invest. 1988 Jan;11(1):21-6. doi: 10.1007/BF03350089. J Endocrinol Invest. 1988. PMID: 2896207
-
Absorption of an aqueous solution of a new synthetic somatostatin analogue administered to man by gavage.Eur J Clin Pharmacol. 1987;33(2):167-71. doi: 10.1007/BF00544562. Eur J Clin Pharmacol. 1987. PMID: 2891532
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical